SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Antifungal stewardship in the UK: where are we now?

Schelenz, S; Agrawal, S; Brady, A; Kiely, G; Riaz, Z; Howes, E; Felton, T; Micallef, C; Tyler, N; Bicanic, T; et al. Schelenz, S; Agrawal, S; Brady, A; Kiely, G; Riaz, Z; Howes, E; Felton, T; Micallef, C; Tyler, N; Bicanic, T; White, PL (2025) Antifungal stewardship in the UK: where are we now? JAC Antimicrob Resist, 7 (1). dlae209. ISSN 2632-1823 https://doi.org/10.1093/jacamr/dlae209
SGUL Authors: Bicanic, Tihana

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (473kB) | Preview

Abstract

BACKGROUND: Antifungal stewardship (AFS) is the judicious use of today's antifungal agents with the aim of improving patient outcomes and preserving their future effectiveness. Antifungal resistance (AFR) is increasing globally, with more patients at risk of Invasive Fungal Disease (IFD), highlighting the urgent need to standardize AFS practices in the UK. The aim of this position paper is to understand the current AFS landscape in the UK. METHODS: A virtual panel discussion was held from September to October 2023 on an online platform followed by a virtual meeting with nine healthcare professionals from across the UK selected for their expertise on IFD management and AFS. The discussion was structured across four topics: current AFS landscape, key elements of an AFS programme, diagnostics and diagnostic stewardship, and unmet needs in education and training. A thematic analysis was carried out. The results represent the collated and summarized views from these activities. RESULTS AND DISCUSSION: Participants reported barriers to implementing AFS and its integration within antimicrobial stewardship (AMS) programmes in the UK. The primary challenge identified was a lack of resources, including funding and staff time. Sub-optimal fungal diagnostics and limited mycology expertise was reported as a barrier to AFS, clinical IFD and AFR surveillance. Approaches to combatting these challenges may include investing in formal mycology networks to serve as centres of clinical expertise and diagnostic hubs. CONCLUSION: National standards for AFS services and associated outcome metrics need to be established to set a benchmark for centres to improve AFS.

Item Type: Article
Additional Information: © The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: JAC Antimicrob Resist
ISSN: 2632-1823
Language: eng
Publisher License: Creative Commons: Attribution-Noncommercial 4.0
PubMed ID: 39741653
Web of Science ID: WOS:001386135500001
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/117047
Publisher's version: https://doi.org/10.1093/jacamr/dlae209

Statistics

Item downloaded times since 08 Jan 2025.

Actions (login required)

Edit Item Edit Item